| (19) |
 |
|
(11) |
EP 2 716 301 A3 |
| (12) |
EUROPEAN PATENT APPLICATION |
| (88) |
Date of publication A3: |
|
16.07.2014 Bulletin 2014/29 |
| (43) |
Date of publication A2: |
|
09.04.2014 Bulletin 2014/15 |
| (22) |
Date of filing: 15.02.2008 |
|
| (51) |
International Patent Classification (IPC):
|
|
| (84) |
Designated Contracting States: |
|
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL
PT RO SE SI SK TR |
|
Designated Extension States: |
|
AL BA MK RS |
| (30) |
Priority: |
16.02.2007 US 901904 P
02.01.2008 US 9796 P
|
| (62) |
Application number of the earlier application in accordance with Art. 76 EPC: |
|
08725722.6 / 2129396 |
| (71) |
Applicant: Merrimack Pharmaceuticals, Inc. |
|
Cambridge, MA 02139 (US) |
|
| (72) |
Inventors: |
|
- Muruganadam, Arumugam
560035 Bangalore (IN)
- Buckler, David
Chester, NJ New Jersey 07930 (US)
- Feldhaus, Michael
Grantham, NH New Hampshire 03753 (US)
- Schoeberl, Birgit
Cambridge, MA Massachusetts 02141 (US)
- Nielsen, Ulrick
Quincy, MA Massachusetts 02169 (US)
|
| (74) |
Representative: Tuxworth, Pamela M. |
|
J A Kemp
14 South Square
Gray's Inn
London WC1R 5JJ
London WC1R 5JJ (GB) |
|
| |
|
| (54) |
Antibodies against ERBB3 and uses thereof |
(57) The present invention provides a novel class of monoclonal antibodies which bind
ErbB3 receptor and inhibit various ErbB3 function. For example, the antibodies described
herein are capable of binding to ErbB3 and inhibiting EGF-like ligand mediated phosphorylation
of the receptor.